Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Neurobiol Dis. 2017 Aug 18;108:115–127. doi: 10.1016/j.nbd.2017.08.009

Figure 3.

Figure 3

Loss of terminal dopaminergic markers in the striatum of LPS-treated mice. Protein levels in striatum for TH, DAT, and VMAT2 on experimental day 5 (A), day 19 (B), and day 36 (C) shows the loss of dopaminergic markers by day 19. (D) Western blots for DAT (D), VMAT2 (E) and TH (F) were quantified by densitometry and normalized to GAPDH levels. Data represent mean ± SEM for 5 mice/group, *p < 0.05 for treatment effect.